Yes, because it may impact potential partners getting involved in P2B combination therapy trial.
ODD in EU gives 10 years market exclusivity amongst other advantages. It is definitely another de-risking event for ANP.
There have also been hints by CEO around one big P2B concurrent trial in US and EU - with results being used to appease both FDA and EMA.
- Forums
- ASX - By Stock
- PER
- One Study Away
PER
percheron therapeutics limited
Add to My Watchlist
5.88%
!
0.8¢

One Study Away, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.8¢ |
Change
-0.001(5.88%) |
Mkt cap ! $8.699M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.8¢ | $16.64K | 2.010M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
24 | 6525662 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 1987416 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 6525662 | 0.008 |
5 | 2239427 | 0.007 |
3 | 2016833 | 0.006 |
3 | 1699997 | 0.005 |
1 | 1475000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1987416 | 4 |
0.010 | 2301175 | 7 |
0.011 | 2440000 | 5 |
0.012 | 2658324 | 5 |
0.013 | 1500000 | 3 |
Last trade - 15.25pm 18/07/2025 (20 minute delay) ? |
Featured News
PER (ASX) Chart |